Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

280.11 +1.56 (+0.56%)
Streaming Delayed Price Updated: 10:14 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential ↗
INSULET CORP (NASDAQ:PODD) shows strong revenue growth, high profitability, and a bullish technical setup, making it a noteworthy candidate for growth investors. 
Via Chartmill
News headline image
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
From Insulet Corporation
Via Business Wire
News headline image
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Stay updated with the S&P500 gap up and gap down stocks on Tuesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
News headline image
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
News headline image
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
From Insulet Corporation
Via Business Wire
News headline image
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue... 
Via StockStory
Topics Economy World Trade
News headline image
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
3 Medical Technology Stocks Outperforming in 2025
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns. 
Via MarketBeat
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
3 Reasons Investors Love Insulet (PODD)
While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to... 
Via StockStory
Topics Stocks
News headline image
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges ↗
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
News headline image
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential ↗
INSULET CORP (NASDAQ:PODD) shows strong growth fundamentals and a bullish technical pattern, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
News headline image
1 Surging Stock with Exciting Potential and 2 to Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
News headline image
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Insulet Corporation
Via Business Wire
News headline image
5 Analysts Assess Insulet: What You Need To Know ↗
 
Via Benzinga
News headline image
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock Meeting Minervini’s Trend Template ↗
INSULET CORP (NASDAQ:PODD) meets Minervini’s Trend Template with strong technicals and high growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
News headline image
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants ↗
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
News headline image
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market. 
Via MarketBeat
Topics Stocks
News headline image
1 Mid-Cap Stock to Target This Week and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Insulet Announces Publication of 2024 Sustainability Report
From Insulet Corporation
Via Business Wire
News headline image
The Trade Desk, Walt Disney, And Hims & Hers Health Are Among Top 11 Large-Cap Gainers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
Top-performing large-cap stocks last week: TTD, HIMS, PODD, FTAI, ULS, UI, ROK, TOST, DIS, MCHP, and ARMK. Analysts raised price forecasts. 
Via Benzinga
News headline image
Stay informed with the top movers within the S&P500 index on Friday. ↗
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Why Insulet (PODD) Stock Is Trading Up Today
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 20.7% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.